Loading
A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05044897 by Sichuan Baili Pharmaceutical Co., Ltd., with 11 participants enrolled, started 2021-10-20 and due to reach its primary completion in 2025-12. Interventions recorded: SI-B001. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SI-B001, SystImmune / Sichuan Biokin, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SystImmune / Sichuan Biokin, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares SystImmune / Sichuan Biokin, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/